Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501410 · ClinicalTrials.gov registry record · Phase 1
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT00501410: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00501410 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00501410, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of a combination of dasatinib, cetuximab, and FOLFOX (5-fluorouracil \[5-FU\], leucovorin \[LV\], and Eloxatin \[oxaliplatin\]) that can be given to patients with metastatic colorectal cancer. The safety of these drugs in combination will also be studied. The goal of the Phase II part of this clinical research study is to learn if dasatinib given in combination with FOLFOX with or without cetuximab can help to control metastatic colorectal cancer.
Interventions
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Cetuximab
- DRUG Dasatinib
- DRUG 5-FU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2007-04-23 |
| Est. Completion | 2017-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00501410
The ClinicalTrials.gov registry entry for NCT00501410 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Leucovorin is the first listed.
NCT00501410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00501410 about?
NCT00501410 is a clinical study titled "FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer". The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of a combination of dasatinib, cetuximab, and FOLFOX (5-fluorouracil \[5-FU\], leucovorin \[LV\], and Eloxatin \[oxaliplatin\]) that can be given to patients with metastatic colorectal cancer. The safe...
What is the current status of trial NCT00501410?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2007-04-23. Estimated completion is 2017-03-03.
What interventions are being tested in trial NCT00501410?
The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), Cetuximab (DRUG), Dasatinib (DRUG), 5-FU (DRUG).
Who is sponsoring clinical trial NCT00501410?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.